Biosimilars are absolutely a hotspot of the global pharmaceutical R&D field in recent years, especially in the patent cliff era. There have been biosimilars sold in the Europe since 2006, but the U.S. did not fill in gaps in system of relevant regulation of biosimilar approval until 2010. Biosimilars have developed more smoothly in the Europe. However, increasingly more biosimilars have formally occupied the U.S. market since the emergence of the first biosimilar Zarxio (biosimilar of Amgen’s Neupogen) in the U.S. market. What are the biosimilars that will change the U.S. pharmaceutical market pattern or even upend the global pharmaceutical market in 2017?
EvaluatePharma has forecast the global top 10 drugs by 2017 sales recently, wherein, seven will be subject to the direct impact of biosimilars.
Global Top 10 Drugs by 2017 Sales (source: EvaluatePharma)